http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Apr 2026 09:02:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html <p>Clarity Pharmaceuticals (ASX: CU6) announced it has signed a Commercial Manufacturing Agreement with Nucleus RadioPharma for its Cu-64 SAR-bisPSMA radiopharmaceutical product, according to a company press release.</p> <p>The agreement covers manufacturing at Nucleus RadioPharma's Rochester, Minnesota facility, which can produce approximately 50,000 patient doses annually. The deal also includes future production at a Spring House, Pennsylvania facility planned to open in 2028, with capacity for up to 600,000 doses per year.</p> <p>The two facilities will provide manufacturing and distribution capabilities to all 50 U.S. states and select international markets including Europe. The agreement builds on an existing partnership established in November 2024 http://www.streetinsider.com/Corporate+News/Clarity+Pharmaceuticals+signs+manufacturing+deal+with+Nucleus+RadioPharma/26309537.html Tue, 14 Apr 2026 09:02:40 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>April 14, 2026</chron></span> /PRNewswire/ -- <b><span value="Australia:CU6" idsrc="xmltag.org" >Clarity Pharmaceuticals</span></b> (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with <span value="ACORN:5021639296" idsrc="xmltag.org" >Nucleus RadioPharma</span>, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html Tue, 14 Apr 2026 09:02:00 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>April 14, 2026</chron></span> /PRNewswire/ -- <b><span value="Australia:CU6" idsrc="xmltag.org" >Clarity Pharmaceuticals</span></b> (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with <span value="ACORN:5021639296" idsrc="xmltag.org" >Nucleus RadioPharma</span>, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html Tue, 14 Apr 2026 09:02:00 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>April 14, 2026</chron></span> /PRNewswire/ -- <b><span value="Australia:CU6" idsrc="xmltag.org" >Clarity Pharmaceuticals</span></b> (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with <span value="ACORN:5021639296" idsrc="xmltag.org" >Nucleus RadioPharma</span>, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html Tue, 14 Apr 2026 09:02:00 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>April 14, 2026</chron></span> /PRNewswire/ -- <b><span value="Australia:CU6" idsrc="xmltag.org" >Clarity Pharmaceuticals</span></b> (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with <span value="ACORN:5021639296" idsrc="xmltag.org" >Nucleus RadioPharma</span>, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html Tue, 14 Apr 2026 09:02:00 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>April 14, 2026</chron></span> /PRNewswire/ -- <b><span value="Australia:CU6" idsrc="xmltag.org" >Clarity Pharmaceuticals</span></b> (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with <span value="ACORN:5021639296" idsrc="xmltag.org" >Nucleus RadioPharma</span>, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html Tue, 14 Apr 2026 09:02:00 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>April 14, 2026</chron></span> /PRNewswire/ -- <b><span value="Australia:CU6" idsrc="xmltag.org" >Clarity Pharmaceuticals</span></b> (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with <span value="ACORN:5021639296" idsrc="xmltag.org" >Nucleus RadioPharma</span>, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html Tue, 14 Apr 2026 09:02:00 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496 http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>April 14, 2026</chron></span> /PRNewswire/ -- <b><span value="Australia:CU6" idsrc="xmltag.org" >Clarity Pharmaceuticals</span></b> (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for ⁶⁴Cu-SAR-bisPSMA with <span value="ACORN:5021639296" idsrc="xmltag.org" >Nucleus RadioPharma</span>, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Clarity+signs+a+Commercial+Manufacturing+Agreement+for+Cu-64+SAR-bisPSMA+with+Nucleus+RadioPharma/26309530.html Tue, 14 Apr 2026 09:02:00 -0400 A.06822034 A.07309385 A.10040885 A.27111662 A.27420030 A.31078550 A.42701208 A.50216392 CU6 O.00030945 O.00067392 O.00832225 O.02097034 O.16629060 O.20026344 O.20043539 O.21107518 O.56101496